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www.cdatm.orgAbstractRegulatory T-cells (Tregs), known for their immune suppressive function, have been reported in higher numbers, with activated
phenotypes and greater potency, in hepatitis B virus (HBV)-related liver diseases than in normal conditions. The numbers, phe-
notypes, and function of intrahepatic and/or tumor-infiltrating Tregs in HBV-related liver diseases also differ from those of Tregs in
the peripheral blood. By inhibiting the function of effector T-cells (Teffs), Tregs play a substantial role in the formation and
maintenance of the liver's suppressive microenvironment, which might account for the progression of HBV-related hepatitis and
hepatocellular carcinoma (HCC). In acute hepatitis B virus infection, Tregs can safeguard the liver from damage at the cost of
prolonged antiviral processes, which results in chronic HBV infection in the liver. Furthermore, Tregs play a role in the development
of cirrhosis, the transformation of cirrhosis to HCC, and the progression and metastasis of HCC. Higher levels of Tregs in the
peripheral blood and/or tumor sites signify a poorer prognosis in HBV-related liver conditions, and observational data from mouse
models and human patients support the theory that depleting Tregs may be therapeutic in HBV-related liver diseases by inducing
antiviral and antitumor immunity.
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Regulatory T-cells (Tregs), comprising 5e10% of
cluster of differentiation (CD) 4þ T-cells, can be
divided into two subsets: natural regulatory T-cells
(nTregs) and induced regulatory T-cells (iTregs).1 The
former subset originates in the thymus in response to
strong T-cell receptor (TCR) engagement with self-
peptides, and the latter, which exerts suppressive
functions comparable to nTregs, is induced from naiveElsevier B.V. on behalf of KeAi Communications Co., Ltd. This is an
ons.org/licenses/by-nc-nd/4.0/).
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tively expressed on the surface of nTregs, CD25 was
the first surface marker discovered to identify Tregs.
CD4þCD25high T-cells constitute a clear Treg popu-
lation, whereas CD4þCD25þ T-cells also comprise
activated T-cells.3 However, other markers can be
used to differentiate the Treg population.4 Forkhead
box protein 3 (Foxp3) is a widely used marker for
Tregs and a definitive marker to define Tregs in pa-
tients with cancer and autoimmune diseases, although
it appears to define conventional activated T-cells,
more broadly, in vitro.5,6 Foxp3 is critical for the
development and function of Tregs in both mice and
humans.7e9 Specifically, the expression of Foxp3 in
Tregs leads to functional and phenotypic differences
between Tregs and effector T-cells (Teffs).10 In
addition to CD25 and Foxp3, Tregs express cytotoxic
T-lymphocyte antigen (CTLA)-4, lymphocyte activa-
tion antigen-3 (LAG-3), interleukin (IL)-7 receptor
alpha-chain (CD127), glucocorticoid induced tumor
necrosis factor receptor (GITR), and T-cell immuno-
globulin and mucin domain 3 (Tim-3).10e14 Some of
these molecular markers are presently used as markers
of activated Tregs.11
Tregs encompass a large population of lymphocytes
that play pivotal roles in maintaining immune ho-
meostasis. These cells play a substantial role in the
development and maintenance of immunological
tolerance by suppressing many cell types, including
CD4þ and CD8þ T-cells, B-cells, dendritic cells (DC),
natural killer (NK) cells, and natural killer T (NKT)
cells.15,16 Tregs mediate allergy suppression, autoim-
mune diseases, immune-mediated transplant rejection,
and pathogen-induced immunopathologies.17 None-
theless, in addition to these advantageous immuno-
regulatory functions of Tregs in the immune system,
they also limit beneficial immune responses by
blocking antigen-specific immunity to specific patho-
genic agents such as hepatitis B virus (HBV) and by
limiting anti-tumor immunity.18 The suppressive
functions of Tregs are clearly antigen dependent
in vivo.11 Antigen-specific Tregs tend to be more
effective in modifying disease than polyclonal Treg
populations.3 Tregs at various stages of diseases and
Tregs in the peripheral blood vs. tumor sites also
display distinct functions.19
Numerous reports have described, in detail, prob-
able mechanisms for Treg regulation of immune
responses.3,7,20e23 Four primary mechanisms are
involved in the suppressive function of Tregs. First,
Tregs suppress immune responses by secreting inhibi-
tory cytokines such as transforming growth factor-b(TGF-b), IL-10, and IL-35. Second, Tregs regulate the
maturation and function of dendritic cells (DCs).
Third, Tregs produce metabolites including nucleotides
that likely inhibit Teffs. Lastly, Tregs show direct
cytolytic action via granzyme and perforin, which is
probably the mechanism underlying cell contact-
mediated suppression.24
China shows the highest incidence of HBV in the
world. HBV infection and hepatocellular carcinoma
(HCC) are also significant health problems world-
wide.25 In China, HCC often develops secondary to
HBV infection. The long-term survival of patients with
HCC is unsatisfactory, even when surgical treatments,
including liver resection and transplantation, are per-
formed. The molecular pathogenesis of HCC second-
ary to HBV infection is not well understood. In adults,
HBV infection mostly leads to self-limiting, acute
hepatitis, resulting in long-lasting protection against re-
infection. However, in 10% of infected adults and 90%
of infected children, HBV is established as a chronic
infection.26 HBV is not cytotoxic and does not injure
the liver directly. Host immunity, therefore, plays a
crucial role in the pathogenesis of HBV infection and
HCC, as well as the host's response to antiviral and
antitumor therapies.21 Considering the substantial role
of Tregs in immune responses against HBV and cancer
cells, understanding the associations between Tregs
and HBV-related liver diseases is essential.
Tregs in acute HBV infection
Characteristics of the intrahepatic virus-specific T-
cell response, including Teffs and Tregs in patients
with acute HBV infection, have seldom been studied
because of the potential for complications related to
standard liver biopsies. However, in the studies that
have been performed, the frequency of Tregs in pa-
tients with acute HBV was lower or comparable to that
of healthy controls during the early acute phase of
infection; Treg levels are then elevated appreciably
throughout the convalescent phase, returning to normal
levels with resolution of the infection.10,27e30 These
fluctuations in the Treg population may be important
marker for patients with HBV infection.
The mechanisms behind the recruitment, activation,
and differentiation of Tregs are under investigation.
Research has shown that CXC chemokine receptor 3
(CXCR3) mediates the recruitment of Tregs to inflamed
human liver tissue via the hepatic sinusoidal endothe-
lium.31 Upregulation of CC chemokine receptor (CCR)
5, CCR4, and CCR8 signifies the activation and differ-
entiation of Tregs.27
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hepatitis associated with HBV infection is not well
understood. The role of Tregs in acute HBV infection
is just beginning to emerge, with adaptive immune
responses in the liver found to be associated with the
resolution of the acute HBV infection.32,33 The
accumulation of Teffs plays a significant role in liver
damage and necro-inflammation during the acute
phase.27 A study by Sprengers et al33 showed a cor-
relation between the levels of intrahepatic CD8þ T-
cells and the degree of liver damage. They observed
that three months after anti-hepatitis B surface anti-
gen (HBsAg) seroconversion, the levels of intra-
hepatic HBV-specific CD8þ T-cells remained high.
Another analysis showed that the induction and
expansion of Tregs could limit excessive immune-
mediated damage in response to HBV infection by
downregulating critical effector cells such as CD8þ T-
cells, which results in viral persistence.34 Stross
et al35 revealed the complex regulatory function of
Tregs during acute infection by depleting Tregs in the
initial stage of adenovirus (Ad) HBV infection, an
infection initiated by an Ad-vectored HBV genome,
in a mouse model. They found that the numbers of
CD4þFoxp3þ Tregs in livers increased rapidlydthe
typical reduction in Tregs during the early acute phase
of infection was not observeddafter the initiation of
HBV replication. Perhaps surprisingly, initial tran-
sient depletion of Tregs failed to enhance the prolif-
eration of HBV-specific Teffs, but it did limit cytokine
production and cytotoxicity of Teffs, alleviating the
liver damage. In this study, depletion of Tregs
increased immune control of acute HBV early in
infection; hepatitis B envelope antigen (HBeAg) and
HBsAg were cleared considerably faster in the serum
of Treg-depleted mice than in that of controls.
Furthermore, early elimination of Tregs improved
recruitment of macrophages and dendritic cells into
HBV-infected livers. Therefore, to some extent, Tregs
alleviate immunopathological liver damage by
downregulating the antiviral activity of Teffs at the
cost of prolonged virus clearance.
Tregs in chronic hepatitis B virus infection
Tregs are related to immune dysfunction in chronic
HBV infections
The local expression of co-inhibitory receptors and
immunosuppressive mediators results in the unique
immune regulatory environment of the liver. This he-
patic suppressive microenvironment consists primarilyof higher numbers of Tregs, upregulated programmed
death-1/programmed death ligand-1 (PD-1/PD-L1)
signals, low levels of Toll-like receptor (TLR)
expression, cytokines such as TGF-b and IL-10, and
non-parenchymal liver cells such as dysfunctional
DCs.29,36 The special immune state of the liver is
closely associated with the strength of an HBV-specific
T-cell response. T-cell exhaustion or dysfunction in
patients with chronic HBV infection has been observed
in many studies. Previous research findings have
indicated that chronic HBV infection is related to an
increase in Tregs and defective CD8þ T-cells that fail
to produce interferon-g (IFN-g).37,38 Help from CD4þ
T-cells is important for the maintenance of CD8þ T-
cell function during chronic infections, but in chronic
HBV infections, CD4þ T-cells also lose this capacity.39
Apart from Tregs and inhibitory receptors that reduce
the functionality of HBV-specific CD8þ T-cells,15 in
chronic infections, T-cell dysfunction also occurs
through functional exhaustion resulting from a high
antigen load and mutations in the virus.39 During most
persistent viral infections, the sustained presence of
viral antigen renders virus-specific T-cells
dysfunctional.40
Based on several reports, it is apparent that innate
immunity is deactivated in the immune tolerant phase
and that adaptive immunity is exhausted in the
apoptotic stage. Consequently, there is no immune-
mediated liver damage in the immune-tolerant phase,
even with HBV replication.41,42 Immune tolerance to
HBV is maintained in patients with chronic infection
but without hepatitis, which is partly controlled by the
host's Tregs.43 Acute exacerbation of chronic HBV
infection is thought to be related to the loss of immune
tolerance.
Features of Tregs in chronic HBV infections
Various markers have been used to identify Tregs in
different studies. Treg levels in patients chronically
infected with HBV can be affected by the choice of
Treg markers.44 Comparisons of Tregs in chronic HBV
infection, healthy controls and other HBV-related liver
diseases are shown in Table 1. In most studies, the
frequency of Tregs in the liver tissues and/or peripheral
blood of patients with chronic HBV infection was
higher than that of asymptomatic HBV-infected pa-
tients, inactive HBsAg carriers, patients acutely
infected with HBV, or healthy controls, which might be
helpful in preventing extensive liver damage. In addi-
tion, intrahepatic Tregs are functionally and pheno-
typically distinct from peripheral blood Tregs in
70 W. Li et al. / Chronic Diseases and Translational Medicine 2 (2016) 67e80patients with chronic HBV infections.19 However,
some studies have shown that the frequency and/or
number of Tregs are not significantly different between
individuals with chronic HBV infections and healthy
controls. One study reported similar frequencies and
suppressive capacities of CD4þCD25þ Tregs in pa-
tients with chronic HBV infections and individuals that
had recovered from HBV infection.45Table 1
Comparisons of Tregs in chronic HBV infection, HC and other HBV-related liver diseases.
Markers Positions Comparisons of Treg frequencies References
CD4þCD45RAFoxp3low PBT and IHT ACLF > AsC and CHB 46
CD4þCD25þFoxp3þ PBT ACLF > CHB 47
CD4þCD25þ PBT ACLF ¼ AHB 48
ACLF > CHB and HC
CD4þCD25þFoxp3þ PBT ACLF > CHB and HC 49,50
CD4þCD25þ PBT ACLF > CHB and HC 28,51
TIT ACLF > CHB and HC
CD4þCD45RAFoxp3high PBT and IHT CHB > HC 46
ACLF > AsC
CD4þCD25high PBT ACLF > CHB and HC 52
CD4þCD25þFoxp3þ PBT CHB > HC 53,54
CD4þFoxp3þ PBT and IHT CHB > HC 55
CD25þCD127low/ PBT CHB > AsC, inactive HBsAg
carriers and HC
44
CD4þCD25þ PBT CHB > HC 42
CD4þCD39þFoxp3þ PBT AsC > ACLF, CHB and HC 56
CD4þCD25þFoxp3þ IHT CHB > HC and resolved HBV 57
IHT AsC > HC and resolved HBV
CD4þCD25þFoxp3þ PBT AHB > CHB > HC 27
CD4þCD25high PBT CHB > AHB and HC 9
CD4þCD127low CD25hi-int PBT CHB > HC 58,59
CD4þCD25þ PBT CHB > HC 60,61
CD4þCD25high PBT CHB > AHB and HC 28,30,62
CD4þCD25high CTLA-4þ PBT CHB ¼ HC 63
CD4þCD25þ PBT CHB ¼ HC 64
Tregs: regulatory T-cells; HBV: hepatitis B virus; HC: healthy control; CD: cluster of differentiation; Foxp3: forkhead box protein 3; PBT: pe-
ripheral blood Tregs; IHT: intrahepatic Tregs; ACLF: acute-on-chronic liver failure; AsC: asymptomatic carriers; CHB: chronic hepatitis B; TIT:
tumor infiltrating Tregs; AHB: acute hepatitis B; CTLA-4: cytotoxic T-lymphocyte antigen-4; >: significantly higher; <: significantly lower; ¼: no
significant difference.Tregs are associated with the progression of chronic
HBV disease
Tregs have not been directly implicated in the pro-
gression of hepatitis disease, including chronic in-
fections or late-stage cirrhosis. However, type 1
regulatory T-cells (Tr1) and nTregs apparently perform
a crucial role in establishing chronic hepatitis and
cirrhosis.65,66
During chronic HBV infection, inflammatory liver
damage is typically not the result of elevated numbers
of infiltrating CD8þ T-lymphocytes, but rather a result
of Fas ligand (Fas-L) expression by Kupffer cells andincreased cytolytic activity of cells in portal areas.67
Within the immune-active phase of chronic HBV
infection, an increase in innate immune cells, including
DCs, can cause liver damage, but is unable to clear the
virus. Nonetheless, adaptive immunity remains
impaired.
The question arises: What is the precise relationship
between Tregs and liver pathology in patients withchronic HBV infections? Normally, liver inflammation
and immune-mediated livery injury can be alleviated
by Tregs; there is a study that demonstrates an inverse
relationship between Tregs and liver inflammation.15
However, in contrast to this finding, Speletas et al68
indicated that Tregs may regulate apoptosis-induced
inflammation. They observed a substantial increase in
Foxp3þ expression in diseases associated with
inflammation.68 Other studies have confirmed an in-
crease in Tregs in liver tissues of patients chronically
infected with HBV with severe hepatitis and suggested
that increased Tregs at the site of inflammation are
associated with chronicity and degree of liver
71W. Li et al. / Chronic Diseases and Translational Medicine 2 (2016) 67e80inflammation.28,52 Some studies have indicated that the
prevalence of CD4þCD25high Tregs in peripheral blood
is indicative of disease severity in patients with chronic
HBV infections or acute-on-chronic liver failure
(ACLF).3,52
Even in the presence of normal serum transaminase,
which may result from an expansion of the Treg pop-
ulation, disease will progress in patients with chronic
HBV infection, suggesting that low levels of liver
inflammation do not correlate with less severe disease.
Fibrogenesis and cirrhosis may be related to decom-
pensation of the immune response.69
This suggests another question: Is there an associa-
tion between Tregs and liver fibrogenesis or cirrhosis?
Many experts have recognized hepatic stellate cells
(HSCs) as the principal effectors in liver fibrogenesis,
but the mechanism underlying this process remains
uncertain. A few reports have suggested that HSCs can
promote liver disease progression by enhancing the
immunosuppressive function of Tregs. However, this
putative association between HSCs and Tregs should be
investigated further.29 An imbalance in Tregs and T
helper (Th) 17 cells also plays an important role in the
occurrence, development, and outcome of chronic HBV
infections.70,71 Several studies have demonstrated that
peripheral Treg and Th17 frequencies in patients with
HBV-related liver fibrosis were both significantly
increased, and their numbers were correlated. The Treg/
Th17 balance might affect the progression of fibrosis in
HBV-infected patients, especially in those with liver
failure resulting from HSC activation and leading to
more severe liver injury.42 A lower Treg/Th17 ratio
always indicates greater liver injury and fibrosis pro-
gression. However, Claassen et al72 did not find any
significant correlation between Tregs and fibrosis.
An inefficient immune responsedone that fails to
clear the virusdleads to chronic inflammation and
tissue remodeling through hepatocytes apoptosis, ne-
crosis, and regeneration, and, finally, pseudolobuli take
shape. Development of chronic inflammation and the
unique liver microenvironment are responsible for the
genomic instability and resulting mutations that pro-
mote neoplastic transformation.73
Tregs in hepatocellular carcinomas
Recruitment of Tregs to the tumor site
The detailed mechanisms underlying recruitment of
Tregs to the tumor microenvironment are not well
understood. Tumor-derived macrophages can produce
CC-chemokine ligand (CCL) 22, which is stronglyassociated with the recruitment of Tregs to tumor
sites.2,74,75 A previous study by Yang et al74 showed
that elevated TGF-b activity associated with the
persistence of HBV in liver tissue can lead to enhanced
production of CCL22 by suppressing the expression of
microRNA-34a (miR-34a). Apart from CCL22, tumor
hypoxia can promote the recruitment of Tregs by
upregulating CCL28.76 The CCR6-CCL20 axis was
also found to recruit Tregs to tumor lesions in a study
by Chen et al.77 These researchers observed high levels
of CCL20-secreting cancer cells and scattered CCL20-
secreting Kupffer cells in tumor regions. Circulating
CD4þCD25þ Tregs, which express CCR6 highly,
selectively migrate to tumors in patients with HCC
because of CCL20 recruitment.77 In addition, CCL17
is responsible for the recruitment of Tregs.2,78
Tregs influence immune dysregulation and tumori-
genesis in HCC
IFN-g-producing CD4þ T helper 1 (Th1) cells and
CD8þ T-cells are believed to be the primary immune
cells responsible for limiting tumor growth and
development by inhibiting and killing tumor cells.
However, a complicated regulatory network contrib-
utes to immune dysregulation in patients with HCC.
Cellular immune suppressive mechanisms in patients
with HCC, including those associated with Tregs, Th
17 cells, CD14þ human leukocyte antigen DR (HLA-
DR) (low/) myeloid-derived suppressor cells, neu-
trophils, and monocytes, promote the development of
an immunosuppressive environment in the
liver.23,39,79,80 There is an additional factor contrib-
uting to T-cell dysfunctiondanergy. Anergy occurs
early in the course of tumor progression and plays a
major part in T-cell impairment in cancers.39,81
Moreover, high virus antigen loads also induce T-cell
functional exhaustion, which likely affects T-cells
function in more invasive cancers. In this article, we
summarize the role of Tregs in defining the special
immune state of patients with HCC.
Many studies have shown that Tregs play important
roles in diminishing the anti-tumor effects of tumor-
infiltrating lymphocytes.39,82,83 Tregs that accumulate
in the tumor site can promote disease progression by
suppressing tissue-derived CD4þCD25 T-cell activa-
tion.84 Chen et al77 showed that Tregs from tumor-
infiltrating lymphocytes, non-tumor-infiltrating lym-
phocytes, and/or peripheral blood inhibit CD4þCD25
T-cell proliferation and INF-g production in a dose-
independent manner. Ormandy et al85 co-cultured
Tregs with activated CD4þCD25 T-cells, and Tregs
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secretion. Tregs can also inhibit tumor antigen-specific
and non-specific CD8þ T-cells. A study by Fu et al86
showed that Tregs in HCC patients inhibited the acti-
vation, proliferation, degranulation, and production of
granzyme A, granzyme B, and perforin from CD8þ T-
cells induced by anti-CD3/CD28 antibodies, resulting
in impaired CD8þ T-cell function. Yang et al87
observed that Tregs in the peri-tumoral region play a
critical role in the progression of HCC by down-
regulating CD8þ cytotoxic T-cell activity. Further, the
findings of Kobayashi et al88 suggest that the preva-
lence of CD8þ tumor-infiltrating lymphocytes de-
creases significantly during hepatocarcinogenesis and
is inversely correlated with that of infiltrating Tregs.
The mechanisms underlying hepatocarcinogenesis
remain unclear. To a certain extent, Tregs in the
tumor microenvironment can increase the frequency of
viral mutation by inducing cellular cytidine deaminase,
and some immune-escape HBV variants have been
associated with hepatocarcinogenesis.89 More impor-
tantly, the suppressive function of Tregs is related
to chronic inflammation in tumors, and chronic in-
flammatory pathways contribute to an inflammation-
necrosis-regeneration process, which is critical to
hepatocarcinogenesis. Chronic inflammation is asso-
ciated not only with hepatocarcinogenesis but also with
the recurrence and metastasis of HCC.89 However,
Zamarron et al80 suggested that Tregs might help
prevent and/or delay inflammation-mediated tumor
development. These conflicting results indicate that
further investigation of the role of CD4þFoxp3þ Tregs
in initial tumor transformation is needed.
In other kinds of cancers such as breast cancer,90 the
accumulation of Tregs at tumor sites correlates with
increased microvessel density and biomarkers that can
accelerate angiogenesis such as vascular endothelialTable 2
Comparisons of Tregs in HCC, HC and other HBV-related liver diseases.
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cantly lower.growth factor (VEGF), which suggests an association
between Tregs and angiogenesis.20 Tregs were also
found to be associated with angiogenesis in ovarian
cancers.76 In HCCs, Huang et al91 discovered that
Tregs were positively correlated with microvessel
density in tumor sites, illustrating the promotion of
HCC progression following angiogenesis fostered by
tumor-infiltrating Tregs. Finally, a study by Ye et al81
showed that higher levels of IL-10, TGF-b1, and
VEGF were detected in tumors than in non-tumor tis-
sues in HCC because of a decrease in effective immune
cells and an increase of suppressor immune cells such
as Tregs. However, additional evidence is needed to
determine whether Tregs contribute to hepatocarcino-
genesis by promoting angiogenesis.
The characteristics of Tregs in HCC
In tumor tissues, most Tregs accumulate in the
parenchymal region of the liver, where the Tregs are
close to liver tumor cells, whereas in non-tumor tis-
sues, the majority of Foxp3þ cells locate in the
mesenchymal region. These results suggest that phys-
ical contact between Tregs and tumor cells may be
necessary for Tregs to exert their regulatory function.77
The average number of intratumoral Tregs is
significantly higher than the number of Tregs in cor-
responding peritumoral tissues,91e93 counterparts of
non-tumor regions in the liver,94 and peripheral
blood.95 Tumor-infiltrating lymphocytes have a higher
proportion of Treg infiltration than that observed in
non-tumor infiltrating lymphocytes.96 The frequencies
of both in HCC, intratumoral and peripheral Tregs,
were higher than those in patients with chronic HBV
infection and healthy controls.93,94,97,98 Comparisons
of Tregs in HCC, healthy controls and other HBV-
related liver diseases are shown in Table 2.omparisons of Treg frequencies References
CC > HC 77,99
CC > HC 60,86,94,100e103
CC > HC 104
CC > CHB > HC 98,105
CC > CHB
CC > HC 77,93
dvanced HCC > early stage HCC 55
CC > CHB > HC 106e108
CC < HC 109
ntrol; HBV: hepatitis B virus; CD: cluster of differentiation; Foxp3:
d Tregs; CHB: chronic hepatitis B; >: significantly higher; <: signifi-
73W. Li et al. / Chronic Diseases and Translational Medicine 2 (2016) 67e80Intrahepatic Tregs more commonly display acti-
vated phenotypes than circulating Tregs.106 Pedroza-
Gonzalez et al106 found that intratumoral Tregs
expressed significantly more inducible co-stimulator
(ICOS) and GITR than Tregs from tumor-free livers
and peripheral blood, indicating a higher state of Treg
activation at the tumor site than in surrounding tis-
sues. The expression of Foxp3 and CTLA was also
significantly higher in HCC patients compared to
patients with chronic HBV infections.98 A study by
Chen et al77 showed that, in addition to Foxp3,
CD45RO, and CTLA-4, Tregs expressed elevated
levels of CD69 and HLA-DR, indicating a terminally
differentiated subpopulation of effector Tregs in
HCC. Another study found increased numbers of
Tregs in the peripheral blood and tumor-infiltrating
lymphocytes and also higher levels of HLA-DR,
GITR, and CD103 expressed in patients with
HCC.110 Ormandy et al85 showed that, in patients
with HCC, increased numbers of Tregs in the pe-
ripheral blood expressed high levels of HLA-DR and
GITR, and low or no CD45RA. Cao et al102 observed
that CD45RA, CD45RO, CD69, CD62L, GITR,
CTLA-4, Ki67 (a proliferation marker), granzyme A,
granzyme B, and Foxp3 expression was upregulated
in CD4þCD25þ T-cells after exposure to HCC cell
lines in vitro.
The function of Tregs in tumor sites is distinct from
that of Tregs in the peripheral blood. Pedroza-
Gonzalez et al106 found that tumor-infiltrating Tregs
were highly activated and were more potent suppres-
sors of tumor-specific and non-tumor-specific CD4þ T-
cell responses. Other researchers have found similar
results. In one study, CD4þCD25þCD127low/
CD49d Tregs were present in higher numbers and
more frequently, displaying a more suppressive effect
in intratumoral areas than in peritumoral regions and
peripheral blood.95 Observations by Cao et al102
strongly suggested that tumor-related factors not only
induced and expanded CD4þCD25þ T-cells, but also
enhanced their suppressor capacities. Specifically,
some results have suggested that Tregs in the peritu-
moral region in HCCs play a critical role in controlling
CD8þ cytotoxic T-cell activity and contribute to the
progression of HCC.86 In addition, another study
showed that Tregs from tumor sites with a high pro-
portion of Foxp3þ cells were more active and potent
than their counterparts from tumor sites with a low
proportion of Foxp3þ cells in HCC.111 Thus, Foxp3
expression may be responsible for the different func-
tions of Tregs.Tregs play a role in the progression and metastasis of
HCC
The role of Tregs in the progression and metastasis
of human liver cancer is just beginning to emerge. One
study showed that intratumoral Tregs accumulated in a
stepwise mannerdfrom viral hepatitis, to pre-
cirrhosis, liver cirrhosis, and early pathologic lesions
such as adenomatous hyperplasia and atypical adeno-
matous hyperplasia, and to early HCC and advanced
HCC, indicating that Treg infiltration is associated with
the formation and progression of hepatocarcino-
genesis.88 The prevalence of circulating Tregs in the
later stages was also found to be higher than in the
earlier stages of HCC.112 Moreover, the frequency of
tumor-infiltrating Tregs in patients with metastasized
tumors was higher than those without metastasis,96 yet
a study showed that there were less intratumoral
Tregs in the advanced stage of HCC than in the early
stage of HCC, whereas the circulating Treg frequency
increased with HCC progression.55 Apart from these
fluctuations in Treg frequencies, a high Treg density is
significantly correlated with clinicopathological fea-
tures such as the absence of tumor encapsulation and
presence of tumor vascular invasion. Thus, Tregs may
be associated with HCC invasiveness.113
Portal vein tumor thrombus (PVTT), which is a
significant risk factor for reduced HCC survival,
severely damages liver function and correlates with
poor prognosis in patients with HCC.114,115 Tregs are
significantly associated with PVTT formation through
the TGF-b-miR-34a-CCL22 axis, which is associated
with tumor progression and metastasis.74
The tolerant immune microenvironment of HCC
facilitates an impaired immune response in patients
with chronic HBV infections and HCC, and is
responsible for the progression and metastasis of HCC.
A substantial surge in the activity of TGF-b signaling,
which has been linked to the persistence of HBV in a
study, might represent the beginning of alterations in
the liver microenvironment.116 TGF-b can suppress the
expression of miR-34a, a recently discovered micro
RNA, resulting in enhanced production of CCL22 and
the recruitment of Tregs (CCL22, in combination with
CCR4, can recruit Tregs).20,77 Finally, Tregs can
modify HCC cells in ways that potentiate their inva-
siveness, such as PVTT formation.114
In addition, a higher rate of PVTT formation was
found in HBV positive patients than those without the
infection. Therefore, HCC initiated by HBV infection
predisposes a patient for the development of PVTT.74
74 W. Li et al. / Chronic Diseases and Translational Medicine 2 (2016) 67e80We speculate that the progression and metastasis of
HCC is a consequence of interactions between many
intricate components. The detailed mechanisms un-
derlying these processes are under investigation.
Tregs are associated with prognosis in HBV-related
liver diseases
Tregs are related to clinicopathological features that
correlate with prognosis in HBV-related liver condi-
tions (Table 3).Table 3
Relationships between Tregs and clinicopathological features of HBV-related diseases.
Markers of Tregs Tregs positions Classes Clinicopathologic features Relation References
CD4þFoxp3þ TIT HCC Liver cirrhosis (þ) 47
CD4þCD25þ TIT HCC Tumor size (þ) 47,56
CD4þFoxp3þ TIT HCC Poorer differentiation (þ) 53,88
CD4þCD25þCD127 PBT HCC Decreased circulating leukocytes
and ferritin; portal vein thrombosis,
heptic vein involvement; advanced clinical
stages evaluated by TNM or BCLC scores
(þ) 72
CD4þCD25þFoxp3þ TIT HCC Preoperative serum AFP level (þ) 117
CD4þFoxp3þ TIT HCC Absence of tumor encapsulation; (þ) 118
presence of tumor vascular invasion
CD4þCD25þFoxp3þ PBT HBeAgþ CHB HBV DNA load (þ) 11
CD4þCD25þFoxp3þ PBT CHB and AsC HBV DNA load (þ) 105




CD4þFoxp3þ PBT CHB HBsAg (þ) 38
CD4þCD45RAFoxp3high PBT CAH HBV DNA load (þ) 61
CD4þCD45RAFoxp3low PBT CAH HAI score (þ) 61
CD4þCD25þFoxp3þ PBT CHB Serum ALT, HBsAg, HBeAg (þ) 30
CD4þCD25high PBT CHB HBV DNA load (þ) 30,67,95
CD4þCD39þFoxp3þ PBT AsC HBV DNA load (þ) 70
Serum ALT ()
CD4þCD25high PBT CHB HBV DNA load (þ) 119
HBeAg No
CD4þFoxp3þIL-10þ PBT CHB HBV DNA load (þ) 106
CD4þCD25þ PBT CHB HBV DNA load (þ) 28
Tregs: regulatory T-cells; HBV: hepatitis B virus; CD: cluster of differentiation; Foxp3: forkhead box protein 3; TIT: tumor infiltrating Tregs; HCC:
hepatocellular carcinoma; PBT: peripheral blood Tregs; TNM: Tumor-Node-Metastasis; BCLC: Barcelona Clinic Liver Cancer; AFP: Alpha fetal
protein; HBeAg: Hepatitis B envelope antigen; CHB: chronic hepatitis B; DNA: deoxyribonucleic acid; AsC: asymptomatic carriers; ACLF: acute-
on-chronic liver failure; IL-10: interleukin-10; INR: international normalized ratio; MELD: Model for end stage liver disease; HBsAg: hepatitis B
surface antigen; CAH: chronic active hepatitis; HAI: histological activity index; ALT: alanine aminotransferase; (þ): positively correlated; ():
negatively correlated; No: no correlation.Recent studies suggest that the proportion of intra-
hepatic Tregs is higher in patients with a higher
chronic HBV load, which might explain the uncon-
trolled viral replication and indicate a poor prog-
nosis.19,66 Patients with chronic HBV infection with
more than 107 HBV copies/ml had higher level ofTregs than subjects with lower viral loads.120 In HCC,
the frequency of peripheral Tregs was found to corre-
late with clinical features associated with a poor
prognosis, including portal vein thrombosis, hepatic
vein involvement, and advanced clinical stages deter-
mined by Barcelona Clinic Liver Cancer scores or
Tumor-Node-Metastasis staging system.104 In addition,
an increase in CD4þCD25þ T-cells in the tumor
microenvironment positively correlates with tumor
sizes,121,122 absence of tumor encapsulation, and
presence of tumor vascular invasion.113Several studies have indicated that tumor-infiltrating
Tregs are increased in HCC and that they can be used
as an independent prognostic factor for patients with
HCC.88,113,123,124 Specifically, survival analyses have
shown that Tregs can indicate HCC prognosis.88,113
The 5-year survival in patients with higher levels of
75W. Li et al. / Chronic Diseases and Translational Medicine 2 (2016) 67e80Tregs in both peripheral blood and tumor tissues was
significantly less than that in the patients with lower
levels of Tregs.125 Low levels of intratumoral Tregs
coupled with high levels of intratumoral activated
cytotoxic T-lymphocytes (CTLs) were associated with
favorable disease-free survival (DFS) and overall sur-
vival (OS) rates. CTLs alone have been reported to be
predictors in many cancers, but in HCC they have only
been associated with improved OS but not DFS.113 In
contrast, a study indicates that CD8þ T-cells have no
prognostic value.88 Results of recent survival analyses
of patients with HCC are summarized in Table 4.Table 4
Relationships between Tregs and survival of patients with HCC.
Tregs markers Class Tregs conditions OS DFS References
CD4þFoxp3þ HCC High TIT and high intratumoral IL-17 (þ) T-cells () () 97
High TIT and high peritumoral IL-17 (þ) T-cells () ()
CD4þFoxp3þ HCC High TIT and low intratumoral CTLs () () 113,121
Low TIT and low peritumoral CTLs (þ) (þ)
Low TIT and high peritumoral CTLs () ()
High CTLs (þ) No
CD4þFoxp3þ HCC High TIT () () 77,88,91,92,113,114
CD4þFoxp3þ Early stage HCC High PBT and TIT () No 55
Balance of CD8þ T-cells and TIT No No
CD4þFoxp3þ HCC High ratio of TIT/CD8þ T-cells () () 123
CD4þCD25þFoxp3þ HCC High TIT No () 124
Tregs: regulatory T-cells; HCC: hepatocellular carcinoma; OS: overall survival; DFS: disease-free survival; CD: cluster of differentiation; Foxp3:
forkhead box protein 3; TIT: tumor infiltrating Tregs; IL-17: interleukin-17; CTL: cytotoxic lymphocyte; PBT: peripheral blood Tregs; (þ): better
prognosis; (): worse prognosis; No: no correlation.In contrast, results of a study by Yu et al126 showed
that a decreased Tregs/Th17 ratio and increased TGF-
b1/IL-17 ratio may be associated with increased sur-
vival and decreased disease progression in HBV-
associated liver cirrhosis patients. In patients with
ACLF, one study indicated that, at the onset of disease,
the Treg to Th17 ratio and Th17 frequency were sig-
nificant predictors of patient survival, with a low Treg/
Th17 ratio suggesting poorer prognosis.47
Therapeutic interventions related to Tregs in HBV-
related liver diseases
Depletion of Tregs during acute viral infection may
prevent viral persistence.10 A report by Stross et al35
noted that Treg depletion accelerates virus clearance.
However, the phenotypic diversity of Tregs makes
them difficult to identify, and there are currently no
specific antibodies against human Tregs to facilitate
targeted depletion.127 More importantly, there are side
effects: Treg depletion may lead to autoimmune re-
actions and increased immune-mediated liver damageresulting from tumor necrosis factor-secreting T-cells
or innate immune cells migrating to the liver.35
In patients with chronic HBV infection, in-
terventions to restore HBV-specific immunity by
inhibiting virus replication with antiviral treatments
such as adefovir have only been partially successful,
but HBV has not been completely cleared. Chronic
HBV infection combined with the establishment of a
tolerant immune microenvironment make functional
restoration of antiviral immunity extremely difficult.
The tolerant immune microenvironment is induced by
a variety of elements; therefore, Tregs should bedepleted in conjunction with other immune thera-
pies,117 e.g., PD-1 and/or LAG-3 blockade39 or
vaccination in combination with administration of cy-
tokines.128 In one study, elimination of Tregs followed
by stimulation with HBV-core 18-27 peptide signifi-
cantly improved anti-virus CTL responses in patients
with chronic HBV infections.59
Eliminating immune tolerance and anergy is one of
the main purposes of tumor immunotherapy.39 Thera-
pies against chronic HBV infection should also be
applied as tumor immunotherapies to rescue T-cells
from exhaustion. Treg function can be inhibited by
targeting functional molecules with antibodies such as
anti-CD25129131 and anti-CTLA-4132 and by inhibit-
ing Treg recruitment and/or expansion,35 which can
increase the number of tumor-reactive T-cells for a
potent anti-tumor response.133e136
To conclude, Tregs participate in the configuration
and maintenance of a suppressive microenvironment in
the liver, which allows HBV infection to progress to
HCC. The numbers of tumor-infiltrating and/or intra-
hepatic Tregs increase gradually from the establishment
Fig. 1. Tregs play a significant role in virus persistence and the formation, progression, and metastasis of HCC. Teffs differentiate in response to
HBVand tumor antigens, and IFN-g-producing CD4þ Th1-cells and CD8þ T-cells are the principle immune cells responsible for inhibiting tumor
growth and development. Tregs are mainly induced from CD4þCD25 T-cells in the periphery, with cytokines such as TGF-b and IL-10
contributing to this process. iTregs and nTregs show similar suppression functions, inhibiting Teffs and reducing the anti-viral and anti-
tumoral immune response. HBV: hepatitis B virus; APC: antigen-presenting cell; CD: cluster of differentiation; IL-10: interleukin-10; TGF-b:
transforming growth factor-b; iTreg: induced regulatory T-cell; nTreg: natural regulatory T cell; Th: T-helper; CHB: chronic hepatitis B; Tregs:
regulatory T-cells; HCC: hepatocellular carcinoma; Teffs: effector T-cells; IFN-g: interferon-g.
76 W. Li et al. / Chronic Diseases and Translational Medicine 2 (2016) 67e80of chronic HBV infection to cirrhosis and HCC. In
addition, activated phenotypes and potent Tregs are
found in tumor sites. The suppressive environment
initiated by Tregs, therefore, is associated with the
chronicity of HBV infection, as well as HCC progres-
sion, metastasis, and prognosis (Fig. 1). Tregs should be
considered a target for HCC therapies. However, the
protocols for Treg management remain to be defined.
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